A5090363961- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Bladder and Urothelial Cancer Treatments
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Melanoma and MAPK Pathways
- Urinary and Genital Oncology Studies
- Sarcoma Diagnosis and Treatment
- Immune cells in cancer
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Computational Drug Discovery Methods
- Advanced Breast Cancer Therapies
- Epigenetics and DNA Methylation
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Adrenal Hormones and Disorders
- Colorectal and Anal Carcinomas
- Estrogen and related hormone effects
- Vascular Tumors and Angiosarcomas
- Peripheral Neuropathies and Disorders
- Gastric Cancer Management and Outcomes
- Long-Term Effects of COVID-19
Azienda Ospedaliero-Universitaria Careggi
2021-2024
University of Siena
2019-2021
University of Chieti-Pescara
2014-2018
Ospedale SS. Annunziata
2016-2017
Background: Immunotherapy has completely changed the treatment of solid tumors. Although immune checkpoint inhibitors (ICIs) seem to be an appealing alternative chemotherapy, especially in elderly patients, due a more tolerable toxicity profile, they can lead peculiar variety immune-related adverse events (irAEs). However, data on tolerability and outcome ICIs are lacking poor accrual clinical trials these patients. Methods: We performed retro-prospective analysis patients treated with...
Aim: Considering the unmet need for counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. Methods: INVIDIa a retrospective, multicenter study, enrolling consecutive advanced outpatients receiving CKI during season 2016–2017. Results: Of 300 patients, 79 received vaccine. The incidence syndrome 24.1% among vaccinated, versus 11.8% controls; odds ratio: 2.4;...
Immune-related adverse events (irAEs) are inflammatory side effects, which can occur during immune-checkpoint(s) inhibitors (ICIs) therapy. Steroids the first-line agents to manage irAEs because of their immunosuppressive properties. However, it is still debated whether or when steroids be administered without abrogating therapeutic efforts immunotherapy.We retrospectively evaluated 146 patients with metastatic non-small cell lung cancer (NSCLC), melanoma and renal carcinoma (RCC) treated...
Aims: It is debated whether the NRAS-mutant melanoma more aggressive than NRAS wildtype. equally controversial metastatic (MM) responsive to checkpoint inhibitor immunotherapy (CII). 331 patients treated with CII as first-line were retrospectively recruited: 162 NRAS-mutant/BRAF wild-type (mut/wt) and 169 wt/wt. We compared two cohorts regarding characteristics of primary disease, disease-free interval (DFI) outcome CII. No substantial differences observed between groups at onset, except for...
BackgroundAdherence to adjuvant endocrine therapy (HT) is suboptimal among breast cancer patients. A high rate of nonadherence might explain differences in survival between clinical trial and practice. Tailored interventions aimed at improving adherence can only be implemented if subgroups patients higher risk poor are identified. Because no data available for Italy, we undertook a large survey on women taking HT cancer.Patients MethodsPatients were recruited from 10 clinics central Italy....
Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are unluckily restricted a small subgroup of patients. Much the inter-individual variability treatment efficacy is as result polymorphisms genes encoding proteins involved drug pharmacokinetics and pharmacodynamics. The nucleotide excision repair (NER) system main defense mechanism for repairing DNA damage caused by carcinogens chemotherapy drugs. Single (SNPs) NER pathway key genes, altering mRNA expression or...
Background: To date, no biomarkers are effective in predicting the risk of developing immune-related adverse events (irAEs) patients treated with immune checkpoint inhibitors (ICIs). This study aims to evaluate association between basal absolute eosinophil count (AEC) and irAEs during treatment ICIs for solid tumors. Methods: We retrospectively evaluated 168 metastatic melanoma (mM), renal cell carcinoma (mRCC), non-small lung cancer (mNSCLC) receiving at our medical oncology unit. By...
Tumors related to hereditary susceptibility seem have an immunosensitive phenotype.We conducted a multicenter retrospective study, investigate if family history of cancer, multiple neoplasms and early onset cancer could be clinical outcomes anti-PD-1/PD-L1 therapy. Activity efficacy data 211 advanced patients (kidney, non-small-cell lung melanoma, urothelium, colorectal HeN), treated at seven Italian centers with agents, were analyzed.In this preliminary report multivariate analyses,...
Although serum sodium concentration, particularly hyponatremia, has been shown to be a prognostic marker of survival in metastatic renal cell carcinoma (mRCC), the impact normal levels not investigated. Herein, we investigate influence normonatremia mRCC patients treated with tyrosine kinase inhibitors (TKIs).For this retrospective study, clinical and biochemical data first-line TKIs for were available from seven Italian cancer centers. We collected natremia at baseline first evaluation...
Background The major challenge for treating non‐squamous (non‐Sq) non‐small cell lung cancer (NSCLC) patients without actionable biomarkers is the actual selection of proper treatment, weighing expected clinical outcomes and safety profile. Methods Consecutive non‐Sq NSCLC were treated with platinum‐pemetrexed (PP) doublets in practice. Subgroup analyses conducted standard (s)PP modified (m)PP (because age, performance status, and/or comorbidities) cisplatin‐based carboplatin‐based PP...
Second-line treatment for advanced non-small-cell lung cancer (NSCLC) patients includes monotherapy with a third-generation cytotoxic drug (CT) or tyrosine kinase inhibitor (TKI). These options are the actual standard EGFR wild-type (WT) status, as mutations achieve greater benefit by use of TKI in first-line treatment. Some clinical trials and meta-analyses investigated comparison between CT second-line, but data conflicting.We designed retrospective trial to gather information about...
Abstract Background Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there no data available for patients progressing to both treatments. The aim of this study was compare active therapeutic options best supportive care (BSC) after progression nivolumab mRCC. Methods In retrospective study, we selected 50 from eight Italian centers. primary endpoint the overall survival (OS) on treatment versus BSC. Secondary endpoints were...
Background/Aim: We performed a multicenter retrospective observational study to investigate the impact of immune checkpoint inhibitors (ICIs) on survival patients with bone metastases (BMs) from renal cell cancer (RCC). Patients and Methods: A total 98 metastatic RCC (mRCC) treated ICIs were retrospectively enrolled. All received standard treatments nivolumab alone or in combination ipilimumab December 2015 March 2022. The primary endpoint was median overall (OS). Results: Forty-three (44%)...
Abstract Background: Therapeutic targeting of the PD-1/PDL-1 axis significantly increases survival melanoma (MM) and non-small cell lung cancer (NSCLC) patients. Despite this unprecedented efficacy, a sizeable proportion MM NSCLC patients fails to benefit from therapy due primary or secondary resistance treatment. In scenario, deepening knowledge on mechanism(s) underlying treatment failure allows design novel, mechanism-based, therapeutic approaches overcome anti-PD-1/PDL-1 therapy. Along...
688 Background: Internationally avelumab is approved as maintenance therapy for patients (pts) with LA/mUC whose disease did not progress after 1L platinum-based chemotherapy. However, 54% of pts progressed on avelumab. Limited data are available predictive biomarker efficacy. Artificial intelligence (AI) methods being increasingly investigated to generate models applicable in clinical practice. In this study, we developed a set machine learning (ML) classifiers and survival analysis...